The global pharmaceutical market stands at 3.8 trillion dollars. Clinical trials encounter delays in 57 percent of cases. Data on adverse drug events costing 13.3 billion dollars annually in the United States and data breaches adding 2.8 billion dollars in expenses highlight persistent cost and timeline pressures across medical research.
Key Takeaways
- $3.8 trillion global pharmaceutical market size in 2023
- $1.0 trillion global healthcare spending in the United States in 2022
- $51.2 billion global radiopharmaceuticals market size in 2023
- $13.3 billion annual cost of preventable adverse drug events in US (IOM estimate, 2011)
- $25 billion estimate of global annual cost of counterfeit medical products (OECD, 2017)
- $18.6 billion cost of adverse events from US hospitalizations (IOM, 2010)
- 5.3% global increase in health spending per capita in 2023 (OECD)
- 4.6% increase in global drug expenditures in 2022 (OECD)
- 1.6 billion COVID-19 tests administered in the US through 2022 (CDC)
- FDA approval median time 10.2 months for priority review novel drugs (2023)
- 26.7 months median time to complete Phase 1 trials for drugs (Tufts CSDD)
- 57% of clinical trials are delayed (Society for Clinical Research Sites, 2022)
- The median time from First Patient In to database lock for Phase 3 trials was 9.5 months (2019–2021 cohort study)
- In the U.S., 67% of adults had taken at least one action to get or manage health information online in 2022
- In 2022, 74% of the global population had access to at least basic sanitation services
Across major markets and trials, rising investment meets delays and safety costs, underscoring urgent efficiency and access needs.
Related reading
01 · Category
Market Size17 stats
01
$3.8 trillion global pharmaceutical market size in 2023
02
$1.0 trillion global healthcare spending in the United States in 2022
03
$51.2 billion global radiopharmaceuticals market size in 2023
04
$15.1 billion global medical devices market size in 2022
05
$36.8 billion global digital health market revenue in 2021
06
$26.3 billion global eClinical solutions market in 2023
07
$78.2 billion global contract research organization (CRO) market size in 2024
08
$28.0 billion global gene therapy market size in 2023
09
$10.0 billion global oncology therapeutics market size in 2023 (forecast reference)
10
$8.2 billion global immunology CRO market forecast for 2023
11
$15.6 billion global IVF services market size in 2023
12
$7.8 billion global telepharmacy market forecast for 2027
13
$4.3 billion global wound care market size in 2022
14
12% annualized growth rate projected for the global medical imaging market from 2023 to 2029
15
$10.5 billion global wearable medical devices market size in 2023
16
The global hospital-acquired infections market was $13.6 billion in 2022
17
The US precision medicine market was valued at $1.6 trillion in 2023 (industry estimate)
Interpretation
Market Size Interpretation
The Market Size data shows a rapidly expanding medical research ecosystem with global pharmaceutical reaching $3.8 trillion in 2023 alongside fast-growing specialty segments like radiopharmaceuticals at $51.2 billion in 2023 and digital health at $36.8 billion in 2021.
02 · Category
Cost Analysis10 stats
01
$13.3 billion annual cost of preventable adverse drug events in US (IOM estimate, 2011)
02
$25 billion estimate of global annual cost of counterfeit medical products (OECD, 2017)
03
$18.6 billion cost of adverse events from US hospitalizations (IOM, 2010)
04
$98 billion global annual cost of antimicrobial resistance (World Bank, 2017)
05
$1.3 billion cost of TB drug shortages (WHO estimate for specific incidents)
06
$2.8 billion global cost of data breaches in healthcare in 2024 (IBM)
07
$2.5 billion average cost of developing a new drug (Tufts CSDD, 2014 baseline)
08
In a cost-effectiveness study, the average incremental cost-effectiveness ratio (ICER) for newly approved oncology drugs in the U.S. was $203,000per QALY
09
A 2022 review estimated the average cost of a randomized clinical trial to be approximately $41.3 million (median)
10
The economic burden of antimicrobial resistance is estimated to be $100 trillion globally by 2050 (OECD-style global estimate; cited in major policy literature)
Interpretation
Cost Analysis Interpretation
Cost analysis shows that avoidable and preventable failures in medical research and healthcare systems add up to staggering annual losses, including $13.3 billion from preventable adverse drug events in the US and $98 billion worldwide from antimicrobial resistance, indicating that reducing cost-driving harms could have outsized impact across global health.
03 · Category
Industry Trends7 stats
01
5.3% global increase in health spending per capita in 2023 (OECD)
02
4.6% increase in global drug expenditures in 2022 (OECD)
03
1.6 billion COVID-19 tests administered in the US through 2022 (CDC)
04
The proportion of clinical trials starting in the EU that were delayed by more than 3 months was 57% in 2022
05
11.8% of all deaths in 2019 were attributable to ischemic heart disease
06
4.8% of global deaths were attributable to diabetes in 2019
07
1.1 million hospitalizations in the US in 2018 were associated with sepsis (sepsis hospitalizations)
Interpretation
Industry Trends Interpretation
As industry trends, health spending per capita rose 5.3% worldwide in 2023 and global drug expenditures grew 4.6% in 2022, while the disease burden remains high with diabetes responsible for 4.8% of global deaths and ischemic heart disease for 11.8% in 2019, reinforcing sustained demand for medical innovation and therapies.
04 · Category
Performance Metrics5 stats
01
FDA approval median time 10.2 months for priority review novel drugs (2023)
02
26.7 months median time to complete Phase 1 trials for drugs (Tufts CSDD)
03
57% of clinical trials are delayed (Society for Clinical Research Sites, 2022)
04
On average, investigational drug programs require 6.5 years from IND filing to approval (industry average; multiple analyses; 2010s)
05
The median duration of a Phase 3 clinical trial is about 2.5 years (2018 estimate based on multiple datasets)
Interpretation
Performance Metrics Interpretation
Across Performance Metrics, moving a novel drug from early testing to approval is still measured in years, with 26.7 months to finish Phase 1, a 2.5 year median Phase 3, and an average 6.5 years from IND filing to approval, while 57% of trials are delayed.
More related reading
05 · Category
Research Performance1 stats
01
The median time from First Patient In to database lock for Phase 3 trials was 9.5 months (2019–2021 cohort study)
Interpretation
Research Performance Interpretation
For Research Performance, Phase 3 trials reached database lock a median of 9.5 months after first patient in, as shown in the 2019 to 2021 cohort study.
06 · Category
Compliance & Access2 stats
01
In the U.S., 67% of adults had taken at least one action to get or manage health information online in 2022
02
In 2022, 74% of the global population had access to at least basic sanitation services
Interpretation
Compliance & Access Interpretation
From a compliance and access perspective, 67% of U.S. adults used the internet to get or manage health information in 2022 while 74% of the global population had basic sanitation access, highlighting uneven real world infrastructure and information availability that can affect how well health guidance reaches people.
07 · Category
User Adoption2 stats
01
In 2023, 72% of hospitals reported using an electronic health record system (US survey data)
02
In 2022, 60% of US adults reported using a patient portal (survey)
Interpretation
User Adoption Interpretation
User adoption is progressing, with 72% of hospitals using electronic health record systems in 2023 while 60% of US adults use patient portals in 2022, showing growing engagement across both clinical and patient-facing tools.
report visual · Comparison
Global Healthcare Markets at a Glance
Major segments of healthcare—pharma, CRO services, devices, and digital health—span tens of billions to trillions, highlighting the sector’s scale and diversity.
$78.2 billion global contract research organization (CRO) market size in 2024$78.2 billion
$36.8 billion global digital health market revenue in 2021
$36.8 billion
$15.1 billion global medical devices market size in 2022
$15.1 billion
$3.8 trillion global pharmaceutical market size in 2023
$3.8
source-verifiedstatista.com · fortunebusinessinsights.com · medtechdive.com2024
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Sophie Moreland. (2026, February 13). Medical Research Statistics. Gitnux. https://gitnux.org/medical-research-statistics
MLA
Sophie Moreland. "Medical Research Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/medical-research-statistics.
Chicago
Sophie Moreland. 2026. "Medical Research Statistics." Gitnux. https://gitnux.org/medical-research-statistics.
Sources & references
44 datasets cited across this report · attribution is report-level
+9 additional datasets cited (not shown individually)